Clinical Trial Update: Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MK-7655 (Relebactam) plus imipenem/cilastatin versus imipenem/cilastatin alone for complicated urinary tract infection; results complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pyelonephritis
• Urinary Tract Infection

Drugs mentioned

• Imipenem/Cilastatin (imipenem/cilastatin)
• MK-7655 (Relebactam) + Imipenem/Cilastatin (Relebactam + Imipenem/Cilastatin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Urinary Tract Infections, Pyelonephritis | Phase 2 | Status: COMPLETED | Results posted: 2019-05-24